Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
18
Stocks News & Analysis
stocks
World’s largest miner benefits from copper boom
stocks
ASX retailer sees weaker sales growth as conditions soften
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,247.80 | 13.10 | 0.14% |
| CAC 40 | 8,509.36 | 70.24 | -0.82% |
| DAX 40 | 26,128.36 | 210.25 | -0.80% |
| Dow JONES (US) | 53,343.40 | 116.38 | -0.22% |
| FTSE 100 | 10,728.04 | 7.74 | 0.07% |
| HKSE | 25,533.38 | 62.23 | 0.24% |
| NASDAQ | 26,289.71 | 355.20 | -1.33% |
| Nikkei 225 | 65,206.26 | 2,254.46 | -3.34% |
| NZX 50 Index | 13,919.27 | 53.09 | 0.38% |
| S&P 500 | 7,691.76 | 53.30 | -0.69% |
| S&P/ASX 200 | 9,046.90 | 18.30 | 0.20% |
| SSE Composite Index | 3,912.17 | 78.13 | -1.96% |